DDInter1770 DDInter119
In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Terfenadine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyaluronidase
Terfenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lasmiditan
Terfenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venlafaxine
Terfenadine {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Terfenadine {u} may lead to a major life threatening interaction when taken with {v} Citalopram
Terfenadine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine
Terfenadine may lead to a major life threatening interaction when taken with Crizotinib
Terfenadine may lead to a major life threatening interaction when taken with Citalopram